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OBJECTIVES: Treatment of abdominal aorta aneurism (AAA)
has, until recently, been performed using open surgery (OS). The
introduction of EVAR can improve the short- and long-term
prognosis of these patients. Our objective was to determine
whether EVAR is cost-effective in the treatment of AAA.
METHODS: A cost-effectiveness analysis of EVAR versus OS
was performed using a simulation model (Markov model) based
on the literature (essentially the EVAR-1 study) plus local expert
opinion and a review of AAA treatment in Spain—published by
the Spanish National HTA. The study population was a hypo-
thetical Spanish population of patients with AAA 5 cm and
tributaries of OS. The model calculated life years gained (LYG),
quality adjusted life years (QALY) and mean cost (C) per patient
at 1, 2, 3 and 4 years for each option. Indicators of cost-
effectiveness derived were C/LYG and C/QALY. The analysis was
performed from the perspective of the Spanish National Health
Service (NHS). a discount of 3.5% was applied to the future costs
and outcomes. Probabilistic Sensitivity Analysis was performed.
RESULTS: Preliminary results showed that EVAR was associated
with a higher effectiveness, with 0.09 and 0.24 LYG at 1 and 4
years vs. OS The mean cost per patient was higher in EVAR vs.
OS, with an incremental cost ranging from €3281 to €3706
depending on the different scenarios, essentially because of the
higher costs for purchasing the stent graft in the EVAR option.
The C/LYG of EVAR was €36,645 to €15,138 and the C/QALY
gained was €29,506 to €22,450 (1 and 4 years respectively).
CONCLUSIONS: EVAR is an efﬁcient alternative to conven-
tional surgery. From one year of follow-up onwards, the cost-
effectiveness ﬁgures are below the threshold of efﬁciency, as
deﬁned in Spain. Further prospective results on QoL Resources
utilization may improve model accuracy.
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OBJECTIVES: Dabigatranetexilate (Pradaxa®) is an oral direct
thrombin inhibitor. Clinical data show that once-daily Dabiga-
tranetexilate 220 mg is as effective as enoxaparin 40 mg qd for
the prophylaxis of venous thromboembolism following total hip
or knee replacement surgeries (THR/TKR). However, an oral
treatment for orthopaedic thromboprophylaxis offers potential
beneﬁts to hospitals when compared to the existing injectible low
molecular heparins (LWMH) in terms of reduced administration
costs. METHODS: A cost minimization analysis was performed
from the perspective of acute care and rehabilitation hospitals in
Germany. Use of Dabigatranetexilate following THR/TKR was
compared to LWMH in six acute care and six rehabilitation
hospitals. Nine hypotheses for possible administrative cost dif-
ferences between a subcutaneaous and an oral anticoagulant
were identiﬁed. Each hypothesis was separately examined and
evaluated in each hospital using process cost analysis. Resource
use and cost data were collected by using the hospitals’ own data
and by interviewing and observing doctors and nurses.
RESULTS: The analysis shows that within the German hospital
system the introduction of the new oral anticoagulation drug like
Dabigatranetexilate might lead to an estimated saving of €2.43
per patient per day in an acute care hospital setting and €1.40 per
patient per day in a rehabilitation hospital. Extrapolating this
data to an acute care hospital that performs 1000 knee and hip
replacements per year, with an average length of stay (LOS) of 10
days, use of an oral anticoagulant could reduce costs by approxi-
mately €24,300 per year. Extrapolating to a rehabilitation
hospital that treats 1000 TKR/THR patients per year, with an
average LOS of 21 days could potentially save the hospital
€29,400 per year. CONCLUSIONS: Oral compared to subcuta-
neous thromboprophylaxis may reduce process costs signiﬁ-
cantly and resulting in high economic advantages for German
hospitals.
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OBJECTIVES: Clinical evidence on statins has demonstrated
that considerable differences exist among various statins regard-
ing clinical efﬁcacy and safety. These differences can lead to
dissimilar economic outcomes from drug therapy using one
brand of statin over another. The objective is to estimate the
cardiovascular events reduction and subsequent cost savings
(direct and indirect costs) of rosuvastatin versus atorvastatin in
hypercholesterolemia treatment from a Canadian perspective.
METHODS: Beneﬁts of reducing LDL-C was incorporated into
a model to calculate reduction in cardiovascular (cardiac and
cerebrovascular) events and resulted economic outcomes. Data
for LDL-C reduction from a head-to-head RCT [Am Heart J
2002;144:1044–51]; rosuvastatin (starting 10 mg) versus atorv-
astatin (starting 10 mg) with up-titration doses; and distribution
of cardiovascular risk for users [N = 100,000, duration 5 years]
in the Canadian population [Clin Invest Med 2007;30:E63–E69].
RESULTS: Rosuvastatin and atorvastatin can prevent 3996
(95%CI) (2801 to 5564) and 3306 (2295 to 4643) deaths,
respectively. Furthermore, cardiovascular events (non-fatal MI
and stroke) can be reduced using rosuvastatin and atorvastatin
by as many as 10,518 and 8,702, respectively. [Number of non-
fatal MI and stroke can be prevented by rosuvastatin are 7193
(5092 to 8902) and 3325 (2384 to 4195), respectively. Number
of non-fatal MI and stroke that can be prevented by atorvastatin
are 5951 (4172 to 7430) and 2751 (1953 to 3501), respectively.]
Reduction in cardiovascular morbidity that can be translated
to CDN$299,129,432 (199,178,100 to 349,942,318) and
$230,980,624 (163,250,686 to 291,973,791) direct cost savings
for the Canadian health care system. Total indirect cost savings
from cardiovascular mortality and morbidity reduction due to
rosuvastatin and atorvastatin therapy were estimated to be as
much as $403,824,733 (254,618,972 to 992,132,183) and
$311,823,842 (196,610,707 to 829,205,566), respectively.
CONCLUSIONS: This modeling study demonstrates that rosu-
vastatin and atorvastatin produce dissimilar clinical outcomes
that can lead to diverse economic outcomes of hyperchole-
sterolemia treatment with these drugs.
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